Aeterna Zentaris subsidiary to develop ComGenex cancer compounds

The compounds are PI3K inhibitors that were created under a joint drug discovery program. As part of the transduction signaling technology, these novel compounds could lead to new highly-effective treatments for some forms of cancer.

Dr Ferenc Darvas, president of ComGenex, commented, “We are proud that a world class oncology therapeutic company such as Echelon is willing to acquire and develop the intellectual property we jointly created. The success of the current drug discovery collaboration creates the basis for further successes. This collaboration has been a win-win relationship for both companies.”

Echelon’s product pipeline is focused on the rapidly emerging field of transduction signaling technology. It has early therapeutic leads (mostly direct PI3K inhibitors) against some forms of cancer and is in a position to deliver new highly-effective oncology therapeutics.